Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.600 +0.030 (+1.91%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,294,509
Open 1.580
Bid (Size) 1.600 (500)
Ask (Size) 1.620 (5,600)
Prev. Close 1.570
Today's Range 1.550 - 1.630
52wk Range 0.8621 - 3.780
Shares Outstanding 142,183,418
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses ↗
On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the company's heavily-shorted stock. 
Via The Motley Fool
Topics Stocks
News headline image
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire

Performance

YTD
+18.5%
+18.5%
1 Month
+8.8%
+8.8%
3 Month
+32.2%
+32.2%
6 Month
-3.6%
-3.6%
1 Year
-13.0%
-13.0%

More News

Read More
The market is filled with gapping stocks in Friday's session. ↗
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally ↗
Via The Motley Fool
Topics Death Regulatory Compliance
News headline image
What a Billionaire Family Office's $16.6 Million Exit From TIC Solutions Signals for Long-Term Investors ↗
Via The Motley Fool
Topics Death Regulatory Compliance
News headline image
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday ↗
Via Benzinga
News headline image
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Unseen Hand: Congressional Leaders Under Fire for Alleged Stock Market Outperformance
Via MarketMinute
Topics Bonds ETFs World Trade
News headline image
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Q3 2025 Earnings Beat and Pipeline Progress ↗
Via Chartmill
Topics Earnings
News headline image
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
Via MarketMinute
Topics Initial Public Offering Regulatory Compliance Workforce
News headline image
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
Via Benzinga
News headline image
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Q2 Cash Tops $300 Million ↗
Via The Motley Fool
News headline image
Allogene Narrows Loss in Fiscal Q2 ↗
Via The Motley Fool
News headline image
Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Narrower-Than-Expected Q2 2025 Loss, Shares Rise Modestly ↗
Via Chartmill
News headline image
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
A Look at Allogene Therapeutics's Upcoming Earnings Report ↗
Via Benzinga
News headline image
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 13, 2025 ↗
Via Benzinga

Frequently Asked Questions

Is Allogene Therapeutics, Inc. - Common Stock publicly traded?
Yes, Allogene Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Allogene Therapeutics, Inc. - Common Stock trade on?
Allogene Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Allogene Therapeutics, Inc. - Common Stock?
The ticker symbol for Allogene Therapeutics, Inc. - Common Stock is ALLO on the Nasdaq Stock Market
What is the current price of Allogene Therapeutics, Inc. - Common Stock?
The current price of Allogene Therapeutics, Inc. - Common Stock is 1.600
When was Allogene Therapeutics, Inc. - Common Stock last traded?
The last trade of Allogene Therapeutics, Inc. - Common Stock was at 01/21/26 04:00 PM ET
What is the market capitalization of Allogene Therapeutics, Inc. - Common Stock?
The market capitalization of Allogene Therapeutics, Inc. - Common Stock is 227.49M
How many shares of Allogene Therapeutics, Inc. - Common Stock are outstanding?
Allogene Therapeutics, Inc. - Common Stock has 227M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.